Ronald Ford, MD
Family Medicine · Winter Haven, FLNPI 1285602474
Payments from drug & device makers
Across 321 payments — averaging $18.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$887
- AstraZeneca$653
- Boehringer Ingelheim$645
- Novo Nordisk$549
- Novartis$502
- Merck$421
- plus $2K from 23 others
What the payments were for
- Food & beverage$5,71098%
- Education$1252%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 63 | $887 |
| AstraZeneca | 39 | $653 |
| Boehringer Ingelheim | 26 | $645 |
| Novo Nordisk | 33 | $549 |
| Novartis | 28 | $502 |
| Merck | 20 | $421 |
| Lilly USA, LLC | 18 | $337 |
| Pfizer | 18 | $327 |
| AbbVie(2 entities) | 14 | $255 |
| Bayer | 8 | $166 |
| Dexcom, Inc. | 3 | $144 |
| GSK | 7 | $128 |
| Exact Sciences | 5 | $97 |
| Esperion Therapeutics, Inc. | 5 | $93 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $92 |
| Kowa Pharmaceuticals America, Inc. | 5 | $74 |
| Astellas Pharma US Inc | 4 | $65 |
| Amarin Pharma, Inc. | 4 | $63 |
| Johnson & Johnson | 3 | $61 |
| Sanofi-aventis U.S. LLC | 3 | $50 |
| Abbott | 2 | $48 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $44 |
| Daiichi Sankyo Inc. | 1 | $22 |
| Mylan Specialty L.p. | 1 | $21 |
| Inari Medical, Inc. | 1 | $21 |
| Sunovion Pharmaceuticals Inc. | 1 | $20 |
| Idorsia Pharmaceuticals US Inc | 1 | $19 |
| Tolmar, Inc. | 1 | $18 |
| Biohaven Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VERQUVO$113
- DEXCOM G7 GSS (161)$101
How this compares
$5,835 in reported general payments places this provider in the 85th percentile of 7,282 family medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 126 | $122,547 |
| EliquisApixaban | 164 | $116,314 |
| OzempicSemaglutide | 64 | $87,299 |
| XareltoRivaroxaban | 89 | $59,355 |
| MyrbetriqMirabegron | 50 | $28,415 |
| TrulicityDulaglutide | 16 | $25,590 |
| EntrestoSacubitril/Valsartan | 15 | $24,338 |
| FarxigaDapagliflozin Propanediol | 19 | $22,481 |
| JanuviaSitagliptin Phosphate | 14 | $21,048 |
| LinzessLinaclotide | 13 | $16,803 |
| Spiriva RespimatTiotropium Bromide | 11 | $10,215 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 16 | $9,078 |
| SymbicortBudesonide/Formoterol Fumarate | 25 | $8,559 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 35 | $5,913 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 20 | $5,521 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Spiriva Respimat | $645 | $132,761137 claims |
| PfizerEliquis | $327 | $116,314164 claims |
| Novo NordiskOzempic | $549 | $87,29964 claims |
| Johnson & JohnsonXarelto | $61 | $59,35589 claims |
| AstraZenecaFarxiga, Symbicort | $653 | $31,04144 claims |
| Astellas Pharma US IncMyrbetriq | $65 | $28,41550 claims |
| Lilly USA, LLCTrulicity | $337 | $25,59016 claims |
| NovartisEntresto | $502 | $24,33815 claims |
| MerckJanuvia | $421 | $21,04814 claims |
| AbbVieLinzess, Synthroid | $255 | $20,77952 claims |
| GSKAnoro Ellipta | $128 | $9,07816 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 7,282 family medicine providers in Florida.
Other family medicine in Winter Haven
- Robinson KoilpillaiWinter Haven$9M
- Hugh ColemanDaytona Beach$115.5M
- Alexander WhiteDaytona Beach$69.7M
- Ronald SurowitzJupiter$38.3M
- Bruce RankinDeland$36.7M
- Keila HooverMiami$33.7M
- John NardandreaOcala$30.8M
- Jorge CasoMiami$22.6M
- Sharrell CooperPalm Coast$16.9M
- Christopher GallowayMelbourne$15.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.